Use of sibutramine (Meridia) in obese patients with Type 2 diabetes is associated with statistically significant weight loss and a decreased hemoglobin A1c

2008-10-16
Loading...
Thumbnail Image

View/Download File

Persistent link to this item

Statistics
View Statistics

Journal Title

Journal ISSN

Volume Title

Title

Use of sibutramine (Meridia) in obese patients with Type 2 diabetes is associated with statistically significant weight loss and a decreased hemoglobin A1c

Published Date

2008-10-16

Publisher

Type

Other

Abstract

Abstract: In a meta-analysis of 8 randomized controlled trials including obese patients with Type 2 diabetes, the addition of sibutramine to standard diabetes therapy resulted in a significant decrease in body weight and hemoglobin A1c.

Description

The information provided in this handout does not necessarily reflect the views of the University of Minnesota Medical School physicians and faculty. These materials are provided for informational purposes only and are in no way intended to take the place of the advice and recommendations of your personal health care provider. You use the information provided in these handouts at your own risk.

Related to

Replaces

License

Series/Report Number

Funding information

Isbn identifier

Doi identifier

Previously Published Citation

Suggested citation

Sandvig, Lisa. (2008). Use of sibutramine (Meridia) in obese patients with Type 2 diabetes is associated with statistically significant weight loss and a decreased hemoglobin A1c. Retrieved from the University Digital Conservancy, https://hdl.handle.net/11299/44284.

Content distributed via the University Digital Conservancy may be subject to additional license and use restrictions applied by the depositor. By using these files, users agree to the Terms of Use. Materials in the UDC may contain content that is disturbing and/or harmful. For more information, please see our statement on harmful content in digital repositories.